Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor
Audrey Bochi-Layec(University of Pennsylvania), Marco Ruella(Parker Institute for Cancer Immunotherapy), Vijay Bhoj(Hospital of the University of Pennsylvania), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania), Sarah McCuaig(Nuffield Orthopaedic Centre), Andreas Agathangelidis(Aristotle University of Thessaloniki), Elisavet Vlachonikola(Aristotle University of Thessaloniki), Anastasia Iatrou(Centre for Research and Technology Hellas), Giulia Gabrielli(Hospital of the University of Pennsylvania), Jaryse Harris(Hospital of the University of Pennsylvania), Guido Ghilardi(Hospital of the University of Pennsylvania), Κώστας Σταματόπουλος(Centre for Research and Technology Hellas), Luca Paruzzo(Hospital of the University of Pennsylvania), Puneeth Guruprasad(Parker Institute for Cancer Immunotherapy), Scott A. Jenks(Emory University), Regina Bugrovsky(Emory University), E. John Wherry(University of Pennsylvania), Jean Lemoine(Hospital of the University of Pennsylvania), Marcos Cases(Hospital of the University of Pennsylvania), Patrizia Porazzi(Hospital of the University of Pennsylvania), Edward M. Behrens(Children's Hospital of Philadelphia), Stephen J. Schuster(Hospital of the University of Pennsylvania), Igñacio Sanz(Emory University), Maria Karypidou(Centre for Research and Technology Hellas), Paolo Ghia(Vita-Salute San Raffaele University), Federico Stella(University of Milan), Sokratis A. Apostolidis(University of Pennsylvania), Portia A. Kreiger(Children's Hospital of Philadelphia), Ki Hyun Kim(Chonnam National University Hwasun Hospital), Ranjani Ramasubramanian(University of Pennsylvania), Yunlin Zhang(Hospital of the University of Pennsylvania), Ivan Cohen(Hospital of the University of Pennsylvania), Huiwu Zhao(Hospital of the University of Pennsylvania), Liping Wang(Chinese Center For Disease Control and Prevention), Eleni Bouziani(National and Kapodistrian University of Athens), Raymone Pajarillo(University of Pennsylvania), Bria Fulmer(Translational Therapeutics (United States))
Cited by 0
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k